Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VeCollal
Ghent, Belgiumvecollal.eu ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
VeCollal is a Belgian biotechnology company that has developed the world's first science-based, vegan alternative to human collagen. Utilizing a proprietary biomimetic technology, the company produces a plant-based amino acid profile that identically matches the composition of Type I human collagen. Their flagship product is designed to stimulate the body's own collagen production, offering a sustainable and ethical alternative to traditional animal-derived collagen supplements. VeCollal primarily operates as a B2B supplier, partnering with global brands in the beauty, health, and wellness sectors to integrate their technology into various consumer products.
- Therapeutic areas
- RheumatologyDermatology
- Modalities
- PeptidesRecombinant protein
- Industry
- Non-Drug Biotech
02
Partnerships
AzelisAminolabsRevive Collagen
Beyond the preview
Go deeper on VeCollal.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VeCollal.